免疫療法藥物市場規模、佔有率、成長分析、按類型、按應用、按給藥途徑、按分銷管道、按最終用戶、按地區 - 產業預測，2024-2031年

2022年全球免疫療法藥物市場規模約為2,474.4億美元，高於2023年的2,853億美元，預測期間（2024-2031年）年複合成長率為15.3%，預計2031年將達7,728.7億美元。

全球免疫療法藥物市場經歷顯著成長，這主要是由慢性病（尤其是糖尿病）患病率上升所推動，根據國際糖尿病聯盟的資料，20-79歲成年人的患病率預計到2021年將達到5%，影響3.7億人。領先的市場參與者越來越注重創新產品開發和策略聯盟，以加強免疫療法研究。 COVID-19 大流行推動對免疫療法相關藥物的需求，2021年 1月發表的研究結果突顯了單株抗體在預防高風險 COVID-19 患者住院方面的功效，並進一步加速了這種成長。免疫治療產品監管核准的快速增加也支持了市場擴張。關鍵的成長要素包括與傳統治療相比，人們越來越偏好標靶治療、生物相似藥的引進、文明病的增加以及消費者對單株抗體的需求不斷成長。此外，研究合作的激增、研究機構的建立以及生物技術和製藥公司的大量研發投資也促進了市場動力。總之，這些動態為未來幾年免疫療法的開發和商業化提供了堅實的前景。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 依細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 課題
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 客戶和購買標準分析
• 價值鏈分析
• 供應鏈分析
• 價格分析
• 專利分析
• 技術分析
• 案例研究分析
• 監管環境

免疫治療藥物市場：依類型

• 市場概況
• 抗體醫藥品
• 抑制劑
• 干擾素和白細胞介素
• 癌症疫苗
• 其他類型

免疫治療市場：依給藥途徑

• 市場概況
• 靜脈注射途徑
• 皮下給藥途徑
• 其他給藥途徑

免疫治療藥物市場：依應用分類

• 市場概況
• 癌症
• 自體免疫疾病與發炎疾病
• 血
• 骨
• 神經
• 其他用途

免疫治療藥物市場：依通路分類

• 市場概況
• 零售藥房
• 網路藥房
• 醫院藥房

免疫治療市場：依最終用戶分類

• 市場概況
• 醫院/診所
• 門診手術中心
• 其他

免疫療法市場：依地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲（MEA）
  • 阿拉伯聯合大公國國家
  • 南非
  • 其他中東、非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Merck & Co., Inc.（United States）
• Johnson & Johnson Services, Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• AstraZeneca（United Kingdom）
• Pfizer Inc.（United States）
• Amgen Inc.（United States）
• Novartis AG（Switzerland）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Bristol-Myers Squibb Company（United States）
• Gilead Sciences, Inc.（United States）
• Takeda Pharmaceutical Company Limited（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• AbbVie Inc.（United States）
• GSK PLC（United Kingdom）
• Immunocore Holdings Plc（United Kingdom）
• Astellas Pharma Inc.（Japan）
• Genmab A/S（Denmark）
• MacroGenics, Inc.（United States）
• Ferring BV（Switzerland）

Global Immunotherapy Drugs Market size was valued at around USD 247.44 billion in 2022 and is expected to rise from USD 285.30 billion in 2023 to reach a value of USD 772.87 billion by 2031, at a CAGR of 15.3% over the forecast period (2024-2031).

The global market for immunotherapy drugs is witnessing significant growth, primarily driven by the rising incidence of chronic diseases, particularly diabetes, which affected an estimated 537 million adults aged 20-79 in 2021 and is projected to escalate to 783 million by 2045, according to the International Diabetes Federation. Major market players are increasingly focusing on innovative product development and strategic partnerships to enhance research in immunotherapy. The COVID-19 pandemic has further accelerated this growth by increasing the demand for immunotherapy-related drugs, exemplified by findings published in January 2021 that highlighted the effectiveness of monoclonal antibodies in preventing hospitalizations for high-risk COVID-19 patients. The surge in regulatory approvals for immunotherapy products also supports market expansion. Key growth factors include the growing preference for targeted therapies over conventional treatments, the introduction of biosimilars, the rise in lifestyle-related disorders, and heightened consumer demand for monoclonal antibodies. Additionally, an upsurge in collaborations, the establishment of research laboratories, and significant R&D investments by biotechnology and pharmaceutical firms contribute to the market's momentum. Together, these dynamics are poised to create a robust landscape for immunotherapy drug development and commercialization in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immunotherapy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immunotherapy Drugs Market Segmental Analysis

Global Immunotherapy Drugs Market is segmented by Type, Route of Administration, Application, Distribution Channel, End User and Region. Based on Type, the market is segmented into Antibody Drugs Inhibitor Drugs, Interferons and Interleukins, Cancer Vaccines, and Other Types. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Other Routes of Administration. Based on Application, the market is segmented into Cancer, Autoimmune and Inflammatory Diseases, Hematology, Osteology, Neurology, and Other Applications. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Immunotherapy Drugs Market

The global immunotherapy drugs market is significantly propelled by the rising prevalence of chronic diseases, notably cancer, autoimmune disorders, and infectious diseases. As lifestyles evolve and populations age, the demand for innovative and effective treatment options surges, creating a substantial market opportunity. Immunotherapy offers promising solutions, often leading to potential cures and improved patient outcomes, which further drives its adoption. Additionally, heightened awareness and advancements in diagnostic techniques contribute to early detection and treatment, thereby increasing the patient pool relying on immunotherapeutic agents. Collectively, these factors are expected to stimulate robust growth in the immunotherapy drugs market.

Restraints in the Global Immunotherapy Drugs Market

The Global Immunotherapy Drugs market faces significant restraints due to the challenging development process associated with these treatments. High costs linked to extensive clinical trials, research, and development pose a considerable barrier, limiting the entry of new players into the market. Additionally, the intrinsic complexity of immune system interactions necessitates personalized or group-oriented therapies, further complicating development and increasing expenses. These combined factors can deter investment and innovation, consequently hindering the emergence of new therapies and slowing overall market growth. The intricate regulatory landscape also contributes to these challenges, creating an environment that is less conducive to rapid advancement in immunotherapy.

Market Trends of the Global Immunotherapy Drugs Market

The Global Immunotherapy Drugs market is increasingly shifting towards personalized immunotherapy, fueled by advancements in precision medicine, genomics, and genetic engineering. This trend enables the development of treatments tailored to individual genetic profiles, disease history, and unique immune system characteristics, enhancing efficacy and minimizing side effects. With promising outcomes from clinical trials, pharmaceutical companies are investing significantly in personalized approaches, anticipating this shift will transform treatment paradigms for a range of conditions, including autoimmune diseases and cancers. As a result, the demand for bespoke immunotherapeutic solutions is set to accelerate, marking a pivotal evolution in the immunotherapy landscape.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Customer & Buying Criteria Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Pricing Analysis
• Patent Analysis
• Technology Analysis
• Case Study Analysis
• Regulatory Landscape

Immunotherapy Drugs Market, By Type

• Market Overview
• Antibody Drugs
• Inhibitor Drugs
• Interferons & Interleukins
• Cancer Vaccines
• Other Immunotherapy Drugs

Immunotherapy Drugs Market, By Route of Administration

• Market Overview
• Intravenous Route of Administration
• Subcutaneous Route of Administration
• Other Routes of Administration

Immunotherapy Drugs Market, By Application

• Market Overview
• Cancer
• Autoimmune & Inflammatory Diseases
• Hematology
• Osteology
• Neurology
• Other Applications

Immunotherapy Drugs Market, By Distribution Channel

• Market Overview
• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

Immunotherapy Drugs Market, By End User

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Immunotherapy Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunocore Holdings Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring BV (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments